Prevalência da Retinopatia Diabética em pacientes com Diabetes Mellitus Tipo 2 na população de Vespasiano
DOI:
https://doi.org/10.34119/bjhrv8n4-320Keywords:
Retinopatia Diabética, Diabetes Tipo 2, hiperglicemia, controle glicêmicoAbstract
O Diabetes Mellitus tipo 2 (DM2) é uma patologia caracterizada por hiperglicemia, devido a perda progressiva de secreção de insulina pelas células beta pancreáticas. Essa doença está associada a complicações macrovasculares e microvasculares, dentre elas a retinopatia diabética (RD). A RD, frequentemente, está presente na população de idade ativa e é a principal causa de cegueira evitável nos países desenvolvidos. A doença possui início insidioso e alta taxa de progressão sendo relacionada, principalmente, à duração do diabetes e nível de controle glicêmico. Faz-se necessário programas públicos de prevenção, diagnóstico e tratamento precoce que visam a melhora do prognóstico da RD, bem como a redução do risco de dano visual irreversível. Desse modo, no presente estudo foram analisados dados extraídos de prontuários referentes aos pacientes previamente diagnosticados com DM2, que participaram do mutirão de retinopatia diabética ocorrido em 02/07/2022, residentes de Vespasiano, Minas Gerais, que realizam tratamento nas unidades básicas de saúde ou com médicos endocrinologistas do município. Tais dados coletados tem como objetivo primário avaliar a prevalência da retinopatia diabética nessa população.
References
⦁ Muzy J, Campos MR, Emmerick I, Silva RS da, Schramm JM de A. Prevalência de diabetes mellitus e suas complicações e caracterização das lacunas na atenção à saúde a partir da triangulação de pesquisas. Cadernos de Saúde Pública [Internet]. 2021 [cited 2022 Sep 30];37(5). Available from:⦁ https://www.scielo.br/j/csp/a/B9Fhg54pjQ677YVx9g3mHwL
⦁ Iser BPM, Stopa SR, Chueiri PS, Szwarcwald CL, Malta DC, Monteiro HO da C, et al. Prevalência de diabetes autorreferido no Brasil: resultados da Pesquisa Nacional de Saúde 2013. Epidemiologia e Serviços de Saúde [Internet]. 2015 Jun [cited 2022 Sep 30];24(2):305–14. Available from:⦁ https://www.scielo.br/j/ress/a/kwqktpkDz3KwqcsLggcPvmM/?lang=pt
⦁ Resources | IDF Diabetes Atlas [Internet]. Diabetesatlas.org. 2021 [cited 2022 Sep 30]. Available from:⦁
⦁ Antonetti DA, Klein R, Gardner TW. Diabetic Retinopathy. New England Journal of Medicine [Internet]. 2012 Mar 29 [cited 2022 Sep 30];366(13):1227–39. Available from:⦁ ⦁ https://www.nejm.org/doi/10.1056/NEJMra1005073?url_ver=Z39.88-2003⦁ &⦁ rfr_id=ori:rid:crossref.org⦁ &⦁ rfr_dat=cr_pub%20%200pubmed
⦁ IDF Diabetes Atlas | Tenth Edition [Internet]. Diabetesatlas.org. 2021 [cited 2022 Sep 30]. Available from:⦁ https://diabetesatlas.org/
⦁ Manejo da retinopatia diabética [Internet]. Diretriz da Sociedade Brasileira de Diabetes - Ed. 2022. 2021 [cited 2022 Sep 30]. Available from:⦁ https://diretriz.diabetes.org.br/manejo-da-retinopatia-diabetica/
⦁ King P, Peacock I, Donnelly R. The UK Prospective Diabetes Study (UKPDS): clinical and therapeutic implications for type 2 diabetes. British Journal of Clinical Pharmacology [Internet]. 1999 Nov [cited 2022 Sep 30];48(5):643–8. Available from:⦁ https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2014359/
⦁ Diabetes Control and Complications Trial (DCCT): Results of Feasibility Study. The DCCT Research Group. Diabetes Care [Internet]. 1987 Jan 1 [cited 2022 Sep 30];10(1):1–19. Available from:⦁ https://diabetesjournals.org/care/article/10/1/1/768/Diabetes-Control-and-Complications-Trial-DCCT
⦁ Rodriguez-Poncelas A, Miravet-Jiménez S, Casellas A, Barrot-De La Puente JF, Franch-Nadal J, López-Simarro F, et al. Prevalence of diabetic retinopathy in individuals with type 2 diabetes who had recorded diabetic retinopathy from retinal photographs in Catalonia (Spain). British Journal of Ophthalmology [Internet]. 2015 Jun 18 [cited 2022 Sep 30];99(12):1628–33. Available from:⦁ https://bjo.bmj.com/content/99/12/1628.long
⦁ Diagnosis and Classification of Diabetes Mellitus. Diabetes Care [Internet]. 2011 Jan 1 [cited 2022 Sep 30];34(Supplement_1):S62–9. Available from:⦁ https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3006051/
⦁ Eduardo. Diretriz SBD 2022 – Sociedade Brasileira de Diabetes – Profissional [Internet]. Diabetes.org.br. 2022 [cited 2022 Sep 30]. Available from:⦁ https://profissional.diabetes.org.br/diretriz-sbd-2022/
⦁ Simó-Servat O, Hernández C, Simó R. Diabetic Retinopathy in the Context of Patients with Diabetes. Ophthalmic Research [Internet]. 2019 [cited 2022 Sep 30];62(4):211–7. Available from:⦁ https://www.karger.com/Article/FullText/499541
⦁ Williams R, Airey M, Baxter H et al. Epidemiology of diabetic retinopathy and macular oedema: a systematic review. Eye.2004. Disponível em: <https://pubmed.ncbi.nlm.nih.gov/15232600/>. Acesso em: 20.Set.2022.
⦁ Malerbi FK, Andrade RE, Morales PH, Stuchi JA, Lencione D, de Paulo JV, et al. Diabetic Retinopathy Screening Using Artificial Intelligence and Handheld Smartphone-Based Retinal Camera. Journal of Diabetes Science and Technology [Internet]. 2021 Jan 12 [cited 2022 Sep 22];16(3):716–23. Available from:⦁ https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9294565/
⦁ Xie J, Ikram MK, Cotch MF, Klein B, Varma R, Shaw JE, et al. Association of Diabetic Macular Edema and Proliferative Diabetic Retinopathy With Cardiovascular Disease. JAMA Ophthalmology [Internet]. 2017 Jun 1 [cited 2022 Sep 22];135(6):586. Available from:⦁ https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5593137/
⦁ Gurgel. Diretrizes e posicionamentos – Sociedade Brasileira de Diabetes – Profissional [Internet]. Diabetes.org.br. 2022 [cited 2022 Oct 3]. Available from:⦁ https://profissional.diabetes.org.br/diretrizes-e-posicionamentos/
⦁ Photocoagulation Treatment of Proliferative Diabetic Retinopathy. Ophthalmology [Internet]. 1981 Jul [cited 2022 Sep 30];88(7):583–600. Available from:⦁ https://www.aaojournal.org/article/S0161-6420(81)34978-1/pdf
⦁ Gross JG, Glassman AR, Jampol LM, Inusah S, Aiello LP, Antoszyk AN, et al. Panretinal Photocoagulation vs Intravitreous Ranibizumab for Proliferative Diabetic Retinopathy. JAMA [Internet]. 2015 Nov 24 [cited 2022 Sep 22];314(20):2137. Available from:⦁ https://jamanetwork.com/journals/jama/fullarticle/2469891
⦁ ADVANCE-Action in Diabetes and Vascular Disease: patient recruitment and characteristics of the study population at baseline. Diabetic Medicine [Internet]. 2005 Jul [cited 2022 Sep 30];22(7):882–8. Available from:⦁ https://onlinelibrary.wiley.com/doi/10.1111/j.1464-5491.2005.01596.x
⦁ Ting DSW, Cheung GCM, Wong TY. Diabetic retinopathy: global prevalence, major risk factors, screening practices and public health challenges: a review. Clinical & Experimental Ophthalmology [Internet]. 2016 Feb 17 [cited 2022 Sep 22];44(4):260–77. Available from:⦁ https://pubmed.ncbi.nlm.nih.gov/26716602/
⦁ Vujosevic S, Aldington SJ, Silva P, Hernández C, Scanlon P, Peto T, et al. Screening for diabetic retinopathy: new perspectives and challenges. The Lancet Diabetes & Endocrinology [Internet]. 2020 Apr [cited 2022 Sep 30];8(4):337–47. Available from:⦁ https://www.thelancet.com/journals/landia/article/PIIS2213-8587(19)30411-5/fulltext
⦁ Franco EM, Silva LN, Rocha LDF, Batista MAA, Sathler YG, Paiva LDT, et al. Revisão bibliográfica: retinopatia diabética / Literature review: diabetic retinopathy. Brazilian Journal of Development [Internet]. 2022 May 6 [cited 2022 Sep 30];8(5):35257–64. Available from:⦁ https://brazilianjournals.com/ojs/index.php/BRJD/article/view/47702
⦁ Ting DSW, Cheung GCM, Wong TY. Diabetic retinopathy: global prevalence, major risk factors, screening practices and public health challenges: a review. Clinical & Experimental Ophthalmology [Internet]. 2016 Feb 17 [cited 2022 Sep 30];44(4):260–77. Available from:⦁ https://onlinelibrary.wiley.com/doi/10.1111/ceo.12696
⦁ Riddle MC, Gerstein HC, Holman RR, Inzucchi SE, Zinman B, Zoungas S, et al. A1C Targets Should Be Personalized to Maximize Benefits While Limiting Risks. Diabetes Care [Internet]. 2018 May 11 [cited 2022 Sep 30];41(6):1121–4. Available from:⦁ https://diabetesjournals.org/care/article/41/6/1121/36488/A1C-Targets-Should-Be-Personalized-to-Maximize
⦁ Rodriguez-Gutierrez R, Gonzalez-Gonzalez JG, Zuñiga-Hernandez JA, McCoy RG. Benefits and harms of intensive glycemic control in patients with type 2 diabetes. BMJ [Internet]. 2019 Nov 5 [cited 2022 Sep 30];l5887. Available from:⦁ https://www.bmj.com/content/367/bmj.l5887.long
⦁ Davies MJ, D’Alessio DA, Fradkin J, Kernan WN, Mathieu C, Mingrone G, et al. Management of Hyperglycemia in Type 2 Diabetes, 2018. A Consensus Report by the American Diabetes Association (ADA) and the European Association for the Study of Diabetes (EASD). Diabetes Care [Internet]. 2018 Oct 5 [cited 2022 Sep 30];41(12):2669–701. Available from:⦁ https://diabetesjournals.org/care/article/41/12/2669/36544/Management-of-Hyperglycemia-in-Type-2-Diabetes
